oDrug Type: Riluzole is a benzothiazole derivative and is classified as a neuroprotective agent.
oMechanism of Action: Riluzole predominantly acts by inhibiting the release of glutamate and inactivating voltage-dependent sodium channels. The primary therapeutic effect is believed to be in conditions characterized by excessive glutamate activity, such as amyotrophic lateral sclerosis (ALS).
oGlutamate Inhibition: By reducing glutamate release, it helps to prevent excitotoxicity, which is the nerve cell damage and death caused by excessive stimulation by neurotransmitters.
oSodium Channel Inactivation: It also stabilizes the inactivated state of sodium channels, which reduces neuronal excitability.